Strategies for Increasing Clozapine Use and Adherence
SAN DIEGO—The antipsychotic medication clozapine is far too often discontinued due to side effects that can be effectively managed, a trio of speakers said at the American Psychiatric Association’s annual meeting Sunday.
Clozapine is the gold standard for the treatment of psychosis and patients would be better served by staying on it and taking steps to alleviate the side effects, the team of psychopharmacology consultants from the California Department of State Hospitals argued.
"Many patients are deprived of adequate clozapine trials due to inadequate management of common nonhematologic adverse effects," their presentation concluded.
Jonathan Meyer, MD, cited research showing that more than 70% of the medical reasons for discontinuing clozapine were other than neutropenia, and included conditions such as pregnancy, fever and cardiac issues.
Reducing Readmissions of Patients With Schizophrenia
Dr. Meyer believes more patients will continue taking clozapine if clinicians show they are more attentive to its adverse effects. That is important, he said, because when patients stop taking clozapine, there is no comparably effective treatment to offer them.
"My question is 'What are you going to give them?' There's a reason they ended up on clozapine," he said. "You really want to think really hard and carefully about this."
Dr. Meyer, along with Jennifer O’Day, MD and George Proctor, MD, outlined several of the side effects and strategies for addressing them.
Sialorrhea: Lower the clozapine dose if possible, or use atropine ophthalmic drops or ipratropium bromide nasal spray to reduce saliva production. Second-line treatments include glycopyrrolate, sugarless chewing gun to increase the rate of swallowing, anticholinergic agents such as trihexyphenidyl, alpha-2 agonists such as clonidine, and alpha-1 antagonists such as terazosin.
Constipation: Consider ordering a kidney, ureter, and bladder x-ray before treatment to document baseline. Begin docusate with clozapine especially if there is evidence of constipation. Encourage adequate fluid intake and minimize other anticholinergics. Add an osmotic laxative and a stimulating laxative if needed. If more intervention is needed, consider beginning lubiprostone.
[pagebreak]
Orthostasis: Use standard or slower dose titration and the lowest effective dose of clozapine. Encourage adequate fluid intake and consider adding sodium chloride. Minimize use of concurrent alpha-1-adrenergic antagonists and benzodiazepines. If patient remains symptomatic, consider volume expansion with 9α-fludrocortisone.
Fever: Do not discontinue clozapine for benign fevers, but it can be held temporarily to conduct a work-up on the fever. Note that 55% of patients experience benign fever and flu-like symptom during the first month of taking clozapine.
Tachycardia: Use standard titration and the lowest effective dose of clozapine, and minimize use of concurrent alpha-1-adrenergic and M1 antagonists. If tachycardia is symptomatic, or persistent with rates of at least 110 beats per minute, it must be treated, and beta blockers are the agents of choice.
Myocarditis: Clozapine must be stopped, but can be retried well after myocarditis is resolved, in collaboration with a cardiologist.
Cardiomyopathy: Clozapine must be stopped and rechallenge is not recommended.
Weight gain: Manage through diet, exercise, and possibly metformin, aripiprazole, or orlistat.
Sedation: Use standard titration, and the lowest effective dose of clozapine. Give the bulk of clozapine at night. Minimize use of concurrent sedating medications especially agents with central muscarinic properties, such as oxybutynin.
Seizures: Do not stop clozapine because of seizures. Instead, reduce it to the prior tolerable dose. Limit the maximum plasma level of clozapine by dividing the daily dose. If needed, consider anticonvulsant treatment, preferably valproic acid.
—Terri Airov
Reference
Meyer J, O’Day J, Proctor G. Managing the nonhematological adverse effects of clozapine. Presented at: the American Psychiatric Association Annual Meeting; May 21, 2017; San Diego, CA.


